Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Small Cell Lung Carcinoma 19Breast Neoplasms 16Sarcoma 12Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 7Carcinoma, Hepatocellular 7Thyroid Neoplasms 6Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Ovarian Neoplasms 5NSCLC 5Carcinoma 5Triple Negative Breast Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Neoplasms 3Glioma 3Cholangiocarcinoma 3Brain Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Platinum-resistant Ovarian Cancer 2

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × anlotinib × Clear all
NCT03946943 2019-07-10

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

The First Hospital of Jilin University

Phase 2 Unknown
25 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡